GlassScriptPhysician profile
Lisa L Rudd
NPI 1477756880
$2,503.22
in general payments reported to CMS, 2019-2025
18 companies · $493 in 2025
The $493 reported for 2025 was more than what 83% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $737 · 2022: $587 · 2023: $448 · 2024: $240 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.93 |
| Education | $184.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $665.46 | 2021-2022 | |
| Astellas Pharma US INC | $419.30 | 2021-2024 | Veozah |
| Evofem Biosciences, INC. | $331.62 | 2022-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $212.86 | 2025 | |
| Madrigal Pharmaceuticals | $137.23 | 2025 | Rezdiffra |
| Amgen INC. | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $101.65 | 2022 | |
| Lilly USA, LLC | $96.83 | 2023 | Mounjaro |
| Organon LLC | $88.81 | 2022-2025 | Nexplanon |
| Pfizer INC. | $85.06 | 2022-2024 | |
| Myovant Sciences INC. | $78.59 | 2022 | |
| Abbvie INC. | $52.63 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $44.01 | 2023-2025 | Myfembree |
| Ascend Therapeutics US, LLC | $17.43 | 2023 | |
| Exeltis, USA INC. | $15.65 | 2023 | Slynd |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $15.56 | 2022 | |
| Amarin Pharma, INC. | $11.56 | 2021 | |
| Genentech USA, INC. | $3.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Rudd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.